Delivery of drugs to eyes is a great challenge to researchers because of a number of barriers in the eye preventing the actual dose from reaching the site. A number of ophthalmic delivery systems have been developed in the past couple of years that are not only new but also safe and reliable and help to overcome all those barriers in the eye which are responsible for the very less bioavailability of drugs. In this review, we tried to focus on current research in ocular delivery of drug substances giving special emphasis to liposomal delivery system. A brief analysis of other novel ocular delivery systems, ocular physiology, and microbial sources of disease are also highlighted herein. We analyzed the various research findings for churning a general idea for novel ocular delivery system and its future use. The novel formulations may overcome the addressed problems of ophthalmic medication and comply with the quality assurance issues. The liposomal delivery is advantageous as they have the ability to entrap both hydrophobic and hydrophilic drugs and are suitable for delivery to both the anterior and posterior segment of the eye. Therefore, the use of this alternative approach is quite a necessity.
SahooSKDilnawazFKrishnakumarS. Nanotechnology in ocular drug delivery. Drug Discov Today2008; 13(3–4): 144–151.
2.
GaudanaRJwalaJBodduSHSet al. Recent perspectives in ocular drug delivery. Pharm Res2009; 26(5): 1197–1216.
3.
Del AmoEMUrttiA. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today2008; 13(3–4): 135–143.
4.
KeisterJCCooperERMisselPJet al. Limits on optimizing ocular drug delivery. J Pharm Sci1991; 80(1): 50–53.
5.
IjazMAhmadMAkhtarNet al. Thiolated α-cyclodextrin: the invisible choice to prolong ocular drug residence time. J Pharm Sci2016; 105: 2848–2854.
6.
MishraGPBaguiMTamboliVet al. Recent applications of liposomes in Ophthalmic drug delivery. J Drug Deliv2011; 2011: 863734.
7.
PatelACholkarKAgrahariVet al. Ocular drug delivery systems: an overview. World J Pharmacol2013; 2(2): 47–64.
8.
GaudanaRAnanthulaHKParenkyKet al. Ocular drug delivery. AAPS J2010; 12(3): 348–360.
9.
GignacDBChiambarettaFMilazzoS. An European perspective on topical ophthalmic antibiotics: current and evolving options. Ophthalmol Eye Dis2011; 3: 29–43.
10.
KhalilRMAbdelbaryGABashaMet al. Design and evaluation of proniosomes as a carrier for ocular delivery of lomefloxacin HCl. J Liposome Res2016; 27(2): 118–129.
11.
KlotzSAPennCCNegveskyGJet al. Fungal and parasitic infections of the eye. Clin Microbial Rev2000; 13(4): 622–685.
12.
OnyewuCAfshariNAHeitmanJ. Calcineurin promotes infection of the cornea by Candida albicans and can be targeted to enhance fluconazole therapy. Antimicrob Agents Chemother2006; 50(11): 3963–3965.
13.
KarstenEWatsonSLFosterLJR. Diversity of microbial species implicated in keratitis: a review. Open Ophthalmol J2012; 6: 110–124.
14.
AlkatanHMMaktabiAAl- HarbyMet al. Candida parapsilosis corneal graft infection from a single eye center: histopathologic report of 2 cases. Saudi J Ophthalmol2015; 29: 303–306.
15.
PeriniGSaettoneMFCarafaMet al. Niosomes as carriers for ophthalmic drugs: in vitro/in vivo evaluation. Boll Chim Farm1996; 135(2): 145–146.
16.
GuinediASMortadaNDMansourSet al. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm2005; 306: 71–82.
17.
RajoriaGGuptaA. In-situ gelling system: a novel approach for ocular drug delivery. Am J Pharm Tech Res2012; 2: 24–53.
18.
GratieriTGelfusoGMRochaEMet al. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur J Pharm Biopharm2010; 75: 186–193.
19.
LiuZLiJNieSet al. Study of an alginate/HPMC-based in-situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm2006; 315: 12–17.
20.
PatravaleVBDateAAKulkarniRM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol2004; 56: 827–840.
21.
PignatelloRBucoloCFerraraPet al. Eudragit RS100®nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci2002; 16: 53–61.
22.
PignatelloRBucoloCPuglisiG. Ocular tolerability of Eudragit RS100® and RL100® nanosuspensions as carriers for ophthalmic controlled drug delivery. J Pharm Sci2002; 91: 2636–2641.
23.
DandagiPKerurSMastiholimathVet al. Polymeric ocular nanosuspension for controlled release of acyclovir: in vitro release and ocular distribution. Iran J Pharm Res2009; 8(2): 79–86.
24.
MohamedMI. Optimization of chlorphenesin emulgel formulation. AAPS J2004; 6(3): 81–87.
25.
AkramMNaqviSBSKhanA. Design and development of insulin emulgel formulation for transdermal drug delivery and its evaluation. Pak J Pharm Sci2013; 26(2): 323–332.
26.
ShenYLingXJianWet al. Formulation and evaluation of cyclosporin A emulgel for ocular delivery. Drug Deliv2015; 22(7): 911–917.
27.
KaurIPGargASinglaAKet al. Vesicular systems in ocular drug delivery: an overview. Int J Pharm2004; 269: 1–14.
28.
LiNZhuangCWangMet al. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int J Pharm2009; 379: 131–138.
29.
KaiserJMImaiHHaakensonJKet al. Nanoliposomal minocycline for ocular drug delivery. Nanomedicine2013; 9: 130–140.
30.
GuptaHAqilM. Contact lenses in ocular therapeutics. Drug Discov Today2012; 17: 522–527.
31.
JungHJChauhanA. Temperature sensitive contact lenses for triggered ophthalmic drug delivery. Biomaterials2012; 33: 2289–2300.
32.
PengC-CKimJChauhanA. Extended delivery of hydrophilic drugs from silicone-hydrogel contact lenses containing vitamin E diffusion barriers. Biomaterials2010; 31: 4032–4047.
33.
AchouriDAlhanoutKPiccerellePet al. Recent advances in ocular drug delivery. Drug Dev Ind Pharm2013; 39(11): 1599–1617.
34.
TayelSAEl-NabarawiMATadrosMIet al. Promising ion sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride: design, in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits. Int J Pharm2013; 443: 293–305.
35.
MorsiNMMohamedMIRefaiHet al. Nanoemulsion as a novel ophthalmic delivery system for acetazolamide. Int J Pharm Sci2014; 6(11): 227–236.
36.
BuHZGukasyanHJGouletLet al. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr Drug Metab2007; 8: 91–107.
37.
GanLHasSShenJet al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: improving preocular retention and ocular bioavailability. Int J Pharm2010; 396: 179–187.
38.
CamposAMDSanchezAAlonsoMJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm2001; 224: 159–168.
39.
IqbalMAMdSSahniJKet al. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target2012; 20(10): 813–830.
40.
GabaBFazilMAliAet al. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration. Drug Deliv2015; 22(6): 691–700.
41.
JaiswalPGidwaniBVyasA. Nanostructured lipid carriers and their current application in current application in targeted drug delivery. Artif Cell Nanomed Biotechnol2016; 44: 27–40.
42.
ZaunerWFarrowNAHainesAM. In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density. J Control Release2010; 71: 39–51.
43.
SoutoEBMullerRH. Lipid nanoparticles (Solid lipid nanoparticles and nanostructured lipid carriers) for cosmetic, dermal, and transdermal applications. In: ThassuDDeleersMPathakYV (eds). Nanoparticulate drug delivery systems. New York; London: CRC Press, 2007, pp. 213–233.
44.
ShidhayeSSVaidyaRSutarSet al. Solid lipid nanoparticles and nanostructured lipid carriers-innovative generations of solid lipid carriers. Curr Drug Deliv2008; 5: 324–331.
45.
MüllerRHShegokarRKeckCM. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr Drug Discov Technol2011; 8: 207–227.
46.
LuoQZhaoJZhangXet al. Nanostructured lipid carrier (NLC) coated with chitosan oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm2011; 403: 185–191.
47.
AraujoJNikolicSEgeaMAet al. Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Colloids Surf. B2011; 88: 150–157.
48.
SivaramAJRajithaPMayaSet al. Nanogels for delivery, imaging and therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol2015; 7: 509–533.
49.
WangGNieQZangCet al. Self-assembled thermoresponsive nanogels prepared by reverse micelle → positive micelle method for ophthalmic delivery of muscone, a poorly water-soluble drug. J Pharm Sci2016; 105: 2752–2759.
50.
Alvarez-RiveraFFernández-VillanuevaDConcheiroAet al. α-lipoic acid in soluplus(®) polymeric nanomicelles for ocular treatment of diabetes-associated corneal diseases. J Pharm Sci2016; 105(9): 2855–2863.
51.
MehnertWMäderK. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev2001; 47: 165–196.
52.
SeyfoddinAAl- KassasR. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev Ind Pharm2013; 39(4): 508–519.
53.
SeyfoddinAShawJAl-KassasR. Solid lipid nanoparticles for ocular drug delivery. Drug Deliv2010; 17: 467–489.
54.
KaurIPKanwarM. Ocular preparations: the formulation approach. Drug Dev Ind Pharm2002; 28: 473–493.
55.
KaurIPRanaCSinghH. Development of effective ocular preparations of antifungal agents. J Ocul Pharmacol Ther2008; 24: 481–493.
56.
CavalliRGascoMRChetoniPet al. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm2002; 238: 241–245.
57.
LeonardiABucoloCDragoFet al. Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabbit. Int J Pharm2015; 478: 180–186.
58.
HippalgaonkarKAdelliGRHippalgaonkarKet al. Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation. J Ocul Pharmacol Ther2013; 29(2): 216–228.
59.
QuintanaARaczkaEPiehlerLet al. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res2002; 19(9): 1310–1316.
60.
PadillaDeJesúsOLIhreHRGagneLet al. Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconjug Chem2002; 13(3): 453–461.
61.
IhreHRPadillaDeJesúsOLSzokaFCet al. Polyester dendritic systems for drug delivery applications: design, synthesis, and characterization. Bioconjug Chem2002; 13: 443–452.
62.
FischerMVögtleF. Dendrimers: from design to application—a progress report. Angew Chem Int Ed1999; 38: 884–905.
63.
AbdelkaderHAlanyRG. Controlled and continuous release ocular drug delivery systems: pros and cons. Curr Drug Deliv2012; 9: 421–430.
64.
SpataroGMalecazeFTurrinCOet al. Designing dendrimers for ocular drug delivery. Eur J Med Chem2010; 45: 326–334.
65.
YaoWSunKMuHet al. Preparation and characterization of puerarin-dendrimer complexes as an ocular drug delivery system. Drug Dev Ind Pharm2010; 36(9): 1027–1035.
66.
KambhampatiSPMishraMKMastorakosPet al. Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells. Eur J Pharm Biopharm2015; 95(Pt B): 239–249.
67.
VandammeTFBrobeckL. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release2005; 102(1): 23–28.
68.
LianTHoRJY. Trends and developments in liposome drug delivery systems. J Pharm Sci2001; 90: 667–680.
69.
LawSLHungHY. Properties of acyclovir-containing liposomes for potential ocular delivery. Int J Pharm1998; 161: 253–259.
70.
TahaEIEl-AnaziMHEl-BagoryIMet al. Design of liposomal colloidal systems for ocular delivery of ciprofloxacin. Saudi Pharm J2014; 22: 231–239.
71.
CortesiRArgnaniREspositoEet al. Cationic liposomes as potential carrier for ocular administration of peptides with anti-herpetic activity. Int J Pharm2006; 317: 90–100.
72.
TorchlinVP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov2005; 4(2): 145–160.
73.
KunoNFujiiS. Recent advances in ocular drug delivery systems. Polymers2011; 3: 193–221.
74.
Ako-AdounvoA-MNagarwalRCOliveiraLet al. Recent patents on ophthalmic nanoformulations and therapeutic implications. Recent Pat Drug Deliv Formul2014; 8(3): 193–201.
